Cergentis is sponsor of the upcoming Cell Therapy Manufacturing & Gene Therapy Congress in Amsterdam between December 5-7.
Our CEO will present the TLA technology and its applications in the complete genetic characterisation of transgenic gene therapy products.
The presentation is scheduled for Day 3 (December 7), between 15.25 and 15.40 in Conference Stream 4.
During the presentation, the following will be discussed:
- Introduction of the TLA technology for targeted complete Next Generation Sequencing
- TLA and its applications in the complete sequencing of transgenes, integration sites and gene editing events
- TLA and the quality control and selection of cell lines and the assessment of their genetic stability and clonality
If you are also attending, we look forward to seeing you there.
For more information about our TLA-based transgene sequencing service, click here.